Format

Send to

Choose Destination
BMC Pharmacol Toxicol. 2017 Aug 11;18(1):61. doi: 10.1186/s40360-017-0168-z.

Short-term treatment with taurolidine is associated with liver injury.

Author information

1
Department of General, Visceral and Vascular Surgery, University Hospital Jena, 07747, Jena, Germany. rene.fahrner@med.uni-jena.de.
2
Center for Sepsis Control and Care (CSCC), University Hospital Jena, 07747, Jena, Germany. rene.fahrner@med.uni-jena.de.
3
Department of General, Visceral and Vascular Surgery, University Hospital Jena, 07747, Jena, Germany.
4
Center for Sepsis Control and Care (CSCC), University Hospital Jena, 07747, Jena, Germany.
5
Department of Anesthesiology and Intensive Care Therapy, University Hospital Jena, 07747, Jena, Germany.
6
Department of Clinical Chemistry and Laboratory Diagnostics, University Hospital Jena, 07747, Jena, Germany.

Abstract

BACKGROUND:

Taurolidine has been used for peritonitis, oncological and catheter-lock treatment because of its anti-inflammatory properties. It has been suggested that taurolidine has no severe side-effects, but after long-term use morphological and functional changes of the liver were reported. The aim of this study was to investigate the effect of short-term use of taurolidine on the liver.

METHODS:

In HepaRG cell cultures and on a novel liver biochip dose-dependent effects of taurolidine treatment on hepatocyte adherence and cell viability was investigated. Furthermore, liver enzymes and interleukin- (IL-) 6 were measured in supernatants. Male rats were treated with low- or high-dose taurolidine, respectively, and compared to controls with physiological saline solution administration regarding blood serum parameters and histology.

RESULTS:

In HepaRG cell cultures, hepatocyte adherence was significantly decreased, cell death and cleaved caspase-3 were significantly increased after administration of taurolidine in a dose-dependent manner. High-dose application of taurolidine led to elevated liver enzymes and IL-6 secretion in hepatic organoid. After 24 h a significant increase of serum GLDH and ASAT was observed in rats treated with high-dose taurolidine treatment.

CONCLUSIONS:

Our results suggest that taurolidine caused liver injury after short-term use in in vitro and in vivo models probably due to direct toxic effects on hepatocytes. Therefore, the taurolidine dose should be titrated in further investigations regarding liver injury and inflammation.

KEYWORDS:

Cytokines; Liver biochip; Liver enzymes; Liver injury; Taurolidine

PMID:
28800748
PMCID:
PMC5553585
DOI:
10.1186/s40360-017-0168-z
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center